Ocular Oncology News

Aura Biosciences announce positive visual acuity results from a phase 1b/2 trial of its cancer drug AU-011 in patients with choroidal melanoma.

A 73-year-old white woman was referred to the retina service at the New England Eye Center for consideration of pars plana vitrectomy and lensectomy in the right eye for a hypermature cataract and angle-closure glaucoma.

An 81-year-old retired teacher presented to the cornea clinic for right eye redness and irritation that started 2 months prior.

PHILADELPHIA — It is essential for ophthalmologists to look into the eye, flip the lid and remove the lesion completely when assessing and treating orbital tumors, according to a speaker here.

PHILADELPHIA — In this Healio Video Perspective from the Wills Eye Conference, Carol L. Shields, MD, discusses updates in uveal melanoma.

The FDA approved tebentafusp-tebn for the treatment of adults with HLA-A*02:01-positive unresectable or metastatic uveal melanoma.

WAIKOLOA, Hawaii — The landscape of ocular oncology is “rapidly evolving” in a way similar to medical oncology, a speaker said during a presentation here.

A 59-year-old woman presented to Lahey Hospital & Medical Center in June 2021 with a several months’ history of bilateral light sensitivity, intermittent watery eyes and blurred vision.

NEW ORLEANS — Older age at presentation may be associated with a significantly decreased risk for germline mutation in children with solitary unilateral retinoblastoma, according to a presenter here.

Reduction in circulating tumor DNA appeared correlated with longer OS among patients with previously treated metastatic uveal melanoma who received tebentafusp, according to study results presented at the virtual ESMO Congress.